pyrazines has been researched along with beraprost in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Clozel, M; Ernst, R; Hess, P; Morrison, K; Studer, R | 1 |
Morrell, N; Sitbon, O | 1 |
Benyahia, C; Boukais, K; Clapp, L; Danel, C; Fabre, A; Gomez, I; Leséche, G; Longrois, D; Norel, X; Silverstein, A | 1 |
Del Pozo, R; Escribano-Subias, P; Hernandez Gonzalez, I | 1 |
El Yafawi, R; Wirth, JA | 1 |
3 review(s) available for pyrazines and beraprost
Article | Year |
---|---|
Pathways in pulmonary arterial hypertension: the future is here.
Topics: Acetamides; Animals; Antihypertensive Agents; Benzamides; Clinical Trials as Topic; Drugs, Investigational; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Epoprostenol; Guanylate Cyclase; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Lisuride; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Piperazines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Serotonin Antagonists; Sulfonamides | 2012 |
The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.
Topics: Acetamides; Antihypertensive Agents; Epoprostenol; Humans; Hypertension, Pulmonary; Pyrazines; Receptors, Epoprostenol | 2017 |
What Is the Role of Oral Prostacyclin Pathway Medications in Pulmonary Arterial Hypertension Management?
Topics: Acetamides; Antihypertensive Agents; Epoprostenol; Humans; Hypertension, Pulmonary; Pyrazines | 2017 |
2 other study(ies) available for pyrazines and beraprost
Article | Year |
---|---|
Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function.
Topics: Acetamides; Animals; Dinoprostone; Dose-Response Relationship, Drug; Epoprostenol; Gastric Emptying; Gastrointestinal Transit; Humans; Iloprost; Male; Muscle Contraction; Pulmonary Artery; Pyrazines; Rats; Receptors, Epoprostenol; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach | 2010 |
A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor.
Topics: Acetates; Aged; Drug Evaluation, Preclinical; Epoprostenol; Female; Humans; Iloprost; In Vitro Techniques; Inhibitory Concentration 50; Male; Middle Aged; Molecular Mimicry; Pulmonary Artery; Pulmonary Veins; Pyrazines; Receptors, Epoprostenol; Receptors, Immunologic; Receptors, Prostaglandin; Receptors, Prostaglandin E, EP4 Subtype; Vasodilation; Vasodilator Agents | 2013 |